Keros Therapeutics price target lowered to $41 from $44 at Scotiabank

Scotiabank analyst Greg Harrison lowered the firm’s price target on Keros Therapeutics (KROS) to $41 from $44 and keeps an Outperform rating on the shares. Keros recently announced the TROPOS trial of KER-012 in patients with pulmonary arterial hypertension is being terminated early due to additional instances of pericardial effusion adverse events, the analyst tells investors. The company has now voluntarily halted dosing in the 1.5 mg/kg treatments and placebo arms, one month after voluntarily halting dosing of the 3.0 mg/kg and 4.5 mg/kg treatment cohorts, the firm adds. Scotiabank still sees the potential for upside, with Takeda (TAK) partnered lead asset elritercept set to initiate enrollment in the phase 3 RENEW trial soon.